<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902019000400113</article-id>
<article-id pub-id-type="doi">10.29193/rmu.35.4.5</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Cannabis medicinal como recurso terapéutico: estudio preliminar]]></article-title>
<article-title xml:lang="en"><![CDATA[Medical cannabis as a therapeutic resource: preliminary study]]></article-title>
<article-title xml:lang="pt"><![CDATA[Cannabis medicinal como recurso terapêutico: estudo preliminar]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Galzerano Guida]]></surname>
<given-names><![CDATA[Julia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Orellana Navone]]></surname>
<given-names><![CDATA[Cecilia Carina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ríos Pérez]]></surname>
<given-names><![CDATA[María Daniela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Coitiño González]]></surname>
<given-names><![CDATA[Ana Laura]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Velázquez Ramos]]></surname>
<given-names><![CDATA[Pablo Mariano]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,CASMU- IAMPP Coordinadora Adicciones e integrante Policlínica VIH ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,ASSE Hospital Maciel Servicio de Neurología]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de la República Facultad de Medicina Cátedra de Medicina Familiar y Comunitaria]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,ASSE SAI-PPL  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>35</volume>
<numero>4</numero>
<fpage>113</fpage>
<lpage>137</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902019000400113&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902019000400113&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902019000400113&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  los productos de Cannabis sativa L poseen una eficacia terapéutica conocida desde la Antigüedad, aunque su tipificación farmacológica data de mediados del siglo XX. Recientemente se regularizó su uso en Uruguay.  Objetivo:  analizar una experiencia clínico terapéutica preliminar con cannabis medicinal (CM) con alto contenido en cannabidiol (CBD).  Método:  estudio epidemiológico observacional y retrospectivo de una cohorte de 355 pacientes que concurrieron a consultar espontáneamente sobre CM en una clínica privada entre agosto de 2016 y diciembre de 2017. Durante la primera entrevista se recogieron datos demográficos, historia clínica, farmacológica, expectativas y experiencia previa con cannabis. Se indicó mayoritariamente cannabis con alto contenido en CBD (5,25% de CBD y 0,2% de tetrahidrocannabinol (THC)). En consultas siguientes, se investigó el acceso al CM y se valoró su respuesta y efectos adversos mediante escalas analógicas. Se utilizó estadística descriptiva.  Resultados:  en la cohorte estudiada predominaron mujeres con edad promedio de 67 años, de nivel educativo terciario. Las patologías de consulta fueron neurológicas (38%), enfermedades reumáticas o artro-degenerativas (37%), neoplasias (13%), psiquiátricas (4%) y misceláneas (8%). La mayoría de estos casos (60,6%) refirió mejoría de sus síntomas y solo 16,3% de la población estudiada presentó efectos adversos de grado leve. Los altos costos y la gestión dificultosa para conseguir el CM fueron causas para no iniciar o abandonar el tratamiento.  Conclusiones:  nuestro estudio preliminar refleja una respuesta terapéutica positiva y sin efectos adversos significativos al CM con alto contenido de CBD. El 60,6% de los pacientes tratados refirió mejoría de sus síntomas. Los factores decisivos para un tratamiento exitoso orientan a facilitar el acceso al CM, mejorando la gestión para su obtención y disminuyendo los costos para una mayor accesibilidad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction: Cannabis Sativa L. products are known to be therapeutically effective since ancient times, despite its pharmacological typification was made in the mid-20th century. Its use was recently regulated in Uruguay.  Objective: to analyse a preliminary clinical-therapeutic experience with MC with high content of cannabidiol (CBD).  Method: epidemiological, observational and retrospective study of a 355 patient cohort who spontaneously consulted to learn about CM at a private clinic, between August 2016 and December 2017. Demographic data, medical records, expectation and previous experience with cannabis were collected in the first interview. In most cases, cannabis with high content of CBD was prescribed (5,25 % CBD and 0,2% THC). In subsequent consultations, access to access to MC was invesrtigated and both response to it and adverse effects were studied by means of analogue scales. The study used descriptive statistics.  Results: in the cohort studied, women with an average age of 67 years old and university studies prevailed. The following conditions motivated consultations: neurological (38%), rheumatic or bone degenerative diseases (37%), neoplasms (13%), psychiatric diseases (4%) and miscelánea (8%). In most cases (60,6%) patients stated symptoms improved and only 16,3% of the populaiton studied presented mild adverse effects. High costs and difficulties in accessing MC were the reasons for not starting or abandoning treatment.  Conclusions: our preliminary study reflects the positive therapeutic response and non significant adverse effects to MC with high content of CBD. 60,6% of patients treated referred improvement in their symptoms. Decisive factors for a successful treatment point at the need to make access to MC easier by improving management to obtain it and reducing costs for a greater accessibility.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução: A eficácia terapêutica dos produtos de Cannabis Sativa L. é conhecida desde a antiguidade, embora sua tipificação farmacológica tenha sido feita a meados do século XX. Seu uso no Uruguai foi regularizado recentemente.  Objetivo: Analisar uma experiencia clínico-tera-pêutica preliminar com CM com alto teor de Cannabidiol (CBD).  Métodos: Estudo epidemiológico observacional e retrospectivo de uma coorte de 355 pacientes que consultaram espontaneamente sobre CM em uma clínica privada no período agosto de 2016 - dezembro de 2017. Durante a primeira entrevista foram coletados dados demográficos, clínicos, farmacológicos, expectativas e experiencia previa com cannabis. Na maioria dos casos indicou-se cannabis com alto teor em CBD (5,25 % de CBD e 0,2 % de THC). Nas consultas seguintes, coletou-se informação sobre o acesso a CM e realizou-se uma avaliação da resposta e dos efeitos adversos utilizando escalas analógicas. Foram utilizados métodos de estadística descritiva.  Resultados: Na coorte estudada predominaram mulheres com idade média de 67 anos, de nível educativo terciário. As razõoes de consulta foram patologias neurológicas (38%), enfermidades reumáticas ou artro-degenerativas (37%), neoplasias (13%), doenças psiquiátricas (4%) e outras (8%). A maioria dos casos (60.6 %) informou melhoria dos sintomas e somente 16.3 % da população estudada apresentou efeitos adversos leves. As causas para não iniciar ou abandonar o tratamento foram os altos custos e as dificuldades para a obtenção da CM.  Conclusões: Este estudo preliminar mostra uma resposta terapêutica positiva e sem efeitos adversos significativos ao CM com alto teor de CBD. 60.6% dos pacientes tratados informou melhoria de sintomas. Os fatores decisivos para um tratamento exitoso mostram a necessidade de facilitar o acesso a CM melhorando a gestão para sua obtenção e diminuindo os custos para aumentar o acesso.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cannabis]]></kwd>
<kwd lng="es"><![CDATA[Marihuana medicinal]]></kwd>
<kwd lng="es"><![CDATA[Plantas medicinales]]></kwd>
<kwd lng="es"><![CDATA[Cannabidiol]]></kwd>
<kwd lng="es"><![CDATA[Aceites vegetales]]></kwd>
<kwd lng="es"><![CDATA[Cannabinoides]]></kwd>
<kwd lng="en"><![CDATA[Cannabis]]></kwd>
<kwd lng="en"><![CDATA[Medical marijuana]]></kwd>
<kwd lng="en"><![CDATA[Plants, medicinals]]></kwd>
<kwd lng="en"><![CDATA[Cannabidiol]]></kwd>
<kwd lng="en"><![CDATA[Plant oils]]></kwd>
<kwd lng="en"><![CDATA[Cannabinoides]]></kwd>
<kwd lng="pt"><![CDATA[Cannabis]]></kwd>
<kwd lng="pt"><![CDATA[Maconha medicinal]]></kwd>
<kwd lng="pt"><![CDATA[Plantas medicinais]]></kwd>
<kwd lng="pt"><![CDATA[Cannabidiol]]></kwd>
<kwd lng="pt"><![CDATA[Óleos vegetais]]></kwd>
<kwd lng="pt"><![CDATA[Canabinoides]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[History of cannabis and its preparations in saga, science, and sobriquet]]></article-title>
<source><![CDATA[Chem Biodivers]]></source>
<year>2007</year>
<volume>4</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1614-48</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanus]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[How and why Cannabis became such famous medicine]]></source>
<year></year>
<conf-name><![CDATA[ Coloquio "El cannabis y los cannabinoids en la medicina]]></conf-name>
<conf-date>27 de octubre de 2017</conf-date>
<conf-loc>Montevideo </conf-loc>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Mackie]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An introduction to the endogenous cannabinoid system]]></article-title>
<source><![CDATA[Biol Psychiatry]]></source>
<year>2016</year>
<volume>79</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>516-25</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elsohly]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Gul]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Constituents of cannabis sativa]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Pertwee]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<source><![CDATA[Handbook of cannabis]]></source>
<year>2014</year>
<page-range>4-19</page-range><publisher-loc><![CDATA[Oxford, UK ]]></publisher-loc>
<publisher-name><![CDATA[Oxford University]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pazos Rodríguez]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Grandes Moreno]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoides y sistema endocannabinoide]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Ramos Atance]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Efectos terapéuticos de los cannabinoides]]></source>
<year>2017</year>
<page-range>7-23</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Complutense de Madrid]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elsohly]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Slade]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemical constituents of marijuana the complex mixture of natural cannabinoids]]></article-title>
<source><![CDATA[Life Sci]]></source>
<year>2005</year>
<volume>78</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>539-48</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bewley-Taylor]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Blickman]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Jelsma]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Auge y caída de la prohibición del cannabis]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Ámsterdam ]]></publisher-loc>
<publisher-name><![CDATA[Trasnational Institute]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<source><![CDATA[Estrategia para la evaluación de resultados y monitoreo de implementación de la Ley 19.172: propuesta]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[FESUR]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<source><![CDATA[Ley 19.172. Marihuana y sus derivados: control y regulación del estado de importación, producción, adquisición, almacenamiento, comercialización y distribución.]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<source><![CDATA[Decreto N° 46/015. Reglamentación de la Ley 19.172 relativa a la regulación y control del cannabis]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<source><![CDATA[Decreto N° 298/2017. Autorización de "venta bajo receta profesional" para las especialidades farmacéuticas con cannabidiol como principio activo]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schachter]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unwanted effects and adverse drug reactions]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical pharmacology]]></source>
<year>2012</year>
<edition>11</edition>
<page-range>110-21</page-range><publisher-loc><![CDATA[Edinburgh ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<collab>National Cancer Institute. National Institutes of Health. Department of Health and Human Services</collab>
<source><![CDATA[Common terminology criteria for adverse events (CTCAE) version 5.0]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Bethesda, MD ]]></publisher-loc>
<publisher-name><![CDATA[NCI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A fifth amendment for the Declaration of Helsinki]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2000</year>
<volume>356</volume>
<numero>9236</numero>
<issue>9236</issue>
<page-range>1123</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<collab>Asociación Médica Mundial</collab>
<source><![CDATA[Declaración de Taipei: investigación sobre las bases de datos, datos masivos y biobancos]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Taipei ]]></publisher-loc>
<publisher-name><![CDATA[AMM]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robaina]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Peyraube]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Cannabis medicinal: la revolución silenciosa]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[Monitor Cannabis Uruguay]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nunberg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kilmer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pacula]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Burgdorf]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An analysis of applicants presenting to a medical marijuana specialty practice in California]]></article-title>
<source><![CDATA[J Drug Policy Anal]]></source>
<year>2011</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reinarman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nunberg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lanthier]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Heddleston]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Who are medical marijuana patients Population characteristics from nine California assessment clinics]]></article-title>
<source><![CDATA[J Psychoactive Drugs]]></source>
<year>2011</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>128-35</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fairman]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in registered medical marijuana participation across 13 US states and District of Columbia]]></article-title>
<source><![CDATA[Drug Alcohol Depend]]></source>
<year>2016</year>
<volume>159</volume>
<page-range>72-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<collab>O'Connell TJ.Bou-Matar CB</collab>
<article-title xml:lang=""><![CDATA[Long term marijuana users seeking medical cannabis in California (2001-2007) demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants]]></article-title>
<source><![CDATA[Harm Reduct J]]></source>
<year>2007</year>
<volume>4</volume>
<page-range>16</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abuhasira]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Schleider]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Mechoulam]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Novack]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly]]></article-title>
<source><![CDATA[Eur J Intern Med]]></source>
<year>2018</year>
<volume>49</volume>
<page-range>44-50</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<source><![CDATA[FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Silver Spring, MD ]]></publisher-loc>
<publisher-name><![CDATA[FDA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flachenecker]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Henze]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zettl]]></surname>
<given-names><![CDATA[UK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nabiximols (THC/CBD oromucosal spray, Sativex(r)) in clinical practice - results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity]]></article-title>
<source><![CDATA[Eur Neurol]]></source>
<year>2014</year>
<volume>71</volume>
<numero>5-6</numero>
<issue>5-6</issue>
<page-range>271-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Badowski]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Yanful]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer]]></article-title>
<source><![CDATA[Ther Clin Risk Manag]]></source>
<year>2018</year>
<volume>14</volume>
<page-range>643-51</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bellnier]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis]]></article-title>
<source><![CDATA[Ment Health Clin]]></source>
<year>2018</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>110-5</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iffland]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Grotenhermen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An update on safety and side effects of cannabidiol a review of clinical data and relevant animal studies]]></article-title>
<source><![CDATA[Cannabis Cannabinoid Res]]></source>
<year>2017</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>139-54</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
